KZR Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Kezar Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.40 |
| 52 Week High | US$11.35 |
| 52 Week Low | US$5.20 |
| Beta | 0.22 |
| 11 Month Change | -4.21% |
| 3 Month Change | 23.75% |
| 1 Year Change | -10.95% |
| 33 Year Change | -94.76% |
| 5 Year Change | -72.89% |
| Change since IPO | -95.83% |
Recent News & Updates
Recent updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08
FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment
Oct 03Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Aug 11Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
Jul 27Kezar Life Sciences appoints Nick Mordwinkin as chief business officer
Jul 11We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Jan 03Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation
Aug 26We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Apr 05Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like
Mar 01Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Jan 25Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
Dec 21
Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Dec 14Shareholder Returns
| KZR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.2% | 4.3% | 1.6% |
| 1Y | -11.0% | 18.8% | 32.3% |
Return vs Industry: KZR underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: KZR underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| KZR volatility | |
|---|---|
| KZR Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KZR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KZR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 58 | Chris Kirk | www.kezarlifesciences.com |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. Fundamentals Summary
| KZR fundamental statistics | |
|---|---|
| Market cap | US$54.21m |
| Earnings (TTM) | -US$95.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs KZR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KZR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$72.35m |
| Gross Profit | -US$72.35m |
| Other Expenses | US$23.42m |
| Earnings | -US$95.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.7% |
How did KZR perform over the long term?
See historical performance and comparison